Arthritis was produced in rats by the intravenous injection of Mycoplasma arthritidis. Metabolic inhibiting antibody and indirect hemagglutinating antibody could not be detected in the sera of arthritic or convalescent animals. (sc) or intravenous (iv) injection of rats with M. arthritidis resulted in the development of resistance to reinfection. Both of these studies failed to demonstrate the presence of neutralizing antibodies in the sera of convalescent animals. The incubation of viable organisms with immune serum prior to injection had no effect on the severity of the disease.
Histological studies of rat arthritis induced by Mycoplasma arthritidis have been well described in the literature (8, 15, 16, 21) , but little detailed work has been reported on antibody response or the mechanisms involved in the development of immunity.
Early studies by Collier (5) and Woglom and Warren (22) indicated that the subcutaneous (sc) or intravenous (iv) injection of rats with M. arthritidis resulted in the development of resistance to reinfection. Both of these studies failed to demonstrate the presence of neutralizing antibodies in the sera of convalescent animals. The incubation of viable organisms with immune serum prior to injection had no effect on the severity of the disease.
More recently, other studies have been conducted by use of the complement fixation (CF) technique (12, 14) . Rats were injected sc with M. arthritidis, and antibody production was measured throughout the development and resolution of the ensuing abscesses. Klieneberger-Nobel (12) showed that the maximal (CF) titers of I Portions of this study were submitted to the University of Utah by J. F. Cahill in partial fulfillment of the requirements of the M. S. degree. Authors (3) a Cloned three times from strain PG27,.Campo, of D. G. Edward.
(Difco) or broth supplemented with 10%O (v/v) horse serum, 5% (v/v) fresh yeast extract, and 1,000 units of penicillin G per ml (2, 9) . The medium used for the metabolic inhibition (MI) tests was further supplemented with 1% (w/v) L-arginine hydrochloride or 1%, (w/v) D-glucose and 0.002% (w/v) phenol red. The arginine broth medium was adjusted to pH 7.2 and the glucose medium to pH 7.6.
Inoculation and bleeding of rats and recording of polyarthritis. Holtzman white male rats weighing 100 to 120 g or 350 to 400 g were used. Mycoplasma suspensions or sterile broth were injected into rats via the caudal vein in 0.5-ml amounts. The severity of arthritis was recorded by scoring the inflammation of each involved joint from 1 to 4. Paralysis and partial paralysis were scored 1 and 0.5, respectively, for each limb involved. Scores for each rat were totaled and recorded as the degree of polyarthritis. The animals were bled initially by cardiac puncture, but because this procedure resulted in a high fatality subsequent bleedings were done via the orbital sinus. The sera were harvested after overnight storage at (1) , was diluted 1:10 and delivered in 0.1-ml amounts to each tube. The volume was brought to 0.9 ml by addition of broth medium. The tubes were incubated aerobically at 37 C until the indicator in the tubes which contained organisms but no antiserum had changed from orange to red, in the case of the arginine broth, or from red to yellow in the case of the glucose broth. The highest serum dilution which prevented a color change was recorded as the end point. In a positive test, the addition of specific antiserum to the medium inhibits mycoplasma growth and subsequent metabolism of arginine or glucose. This is manifested by failure of the indicator to change color.
Indirect hemagglutination (IHA) test. The method used was that described by Taylor-Robinson et al. (20) . Passive immunizaton. Rats weighing 100 to 120 g were grouped and injected iv as follows: group 1, 0.7 ml of pooled normal rat serum; group 2, 0.7 ml of rat antiserum taken from animals exhibiting severe mycoplasmal polyarthritis; and group 3, 0.7 ml of rat antiserum absorbed with M. arthritidis antigen. The antiserum was absorbed by mixing 11 ml of serum and I ml of concentrated antigen on a shaker at 37 C. After 2 hr, the mixture was stored for 18 hr at 4 C and then centrifuged to remove the precipitate (6) . The procedure was repeated once more. Control, untreated rats were designated group 4.
At 3 hr after iv injection of the sera, all groups of rats were injected intravenously with 1.4 X 1010 CFU of viable M. arthritidis.
RESULTS
Iv inoculation of rats with M.arthritidis strain 158 P10. Groups of rats weighing 100 to 120 g were injected iv with 6 X 106, 6 X 107, 6 X 108, and 6 X 109 CFU of M. arthritidis. After injection, serum samples were taken from the animals at 4, 8, and 14 days, and thereafter once each week until 21 weeks. Tests for CF antibody titers were conducted on the individual sera from those animals which survived for the duration of the experiment. The deaths which occurred during the early part of the experiment wore due to the trauma of cardiac puncture. Arthritis scores and CF titers obsved were averaged and 95% confidence limits were calculated by t distribution (23) . The severity of arthritis and the levels of complement-fixing antibodies were proportional to the number of organisms injected. No arthritis occurred when an inoculum of 6 X 106 CFU of M. arthritidis was injected, although one animal developed paralysis. However, complementfixing antibody titers averaging 1:160 were detected 4 days after injection. The results obtained with the larger inocula are recorded in Fig. 1-3 . Rats injected with these doses produced mean CF titers of 1:1,280 to 1:2,560 after 4 days. To determine more exactly the time at which complement-fixing antibody was first produced, 10 animals were given iv injections with M. arthritidis and bled after 12, 24, 48, 72, and 144 hr. Complement-fixing antibody was not detected until 72 hr after injection of the organisms.
After the initial rise in CF antibody, considerable variation in the titers was observed, presumably due to periodic septicemias. This variation was also apparent upon examination of the antibody responses of individual animals.
Of considerable importance was the finding that complement-fixing antibody titers were usually high at the onset of arthritis and were sometimes present before the clinical symptoms of the disease were evident. Rats inoculated with 6 X 107 CFU of M. arthritidis did not develop arthritis until 5 to 8 days. The mean CF titers of these animals after 4 days was 1:1280.
With doses of 6 X 108 and 6 X 109 CFU, complement-fixing antibody titers of 1:40,960 were commonly produced between 4 and 8 weeks after injection. The antibody titers gradually declined after 8 weeks, although they remained at fairly high levels (1:320 to 1:1,280) until completion of the experiment at 21 weeks. The data obtained using the various inocula are summarized in Table 2 .
For the purposes of comparison, groups of rats were injected with the same doses of suspensions of Formalin-killed M. arthritidis. The animals were bled at intervals up to 5 weeks (Table 3) . Complement-fixing titers were much lower with the Formalin-killed organisms, and they reached significant levels only after In another experiment, untreated rats and rats injected iv with Formalin-killed suspensions of M. arthritidis were challenged by iv injection 5 weeks later with 4 X 1010 CFU of viable organisms (Table 5) . Animals exhibiting CF titers of 1:80 or greater were completely resistant to reinfection. Animals with lower CF titers developed arthritis which was less severe than that of the controls.
An experiment was set up to measure the immunity induced by the sc injection of rats with M. arthritidis strain 158 PIO ( Fig. 4 . Untreated rats and rats injected with normal serum developed severe arthritis, whereas those inoculated with anti-158 PIO rat serum exhibited significantly less arthritis. Absorption of the antiserum with M. arthritidis antigen did not significantly alter its protective properties.
The experiment was repeated using a different batch of convalescent serum. In this case, the original CF titer of 1:5,120 was reduced to 1:10 by the absorption procedure. As before, absorbed serum still possessed protective properties.
For the purposes of comparison, the protective properties of rabbit antiserum against M.
arthritidis were investigated. The rabbit antiserum used had a homologous CF titer of 1:10,240. Groups of rats were treated with 0.5-ml amounts of undiluted serum and of 1:5 and 1:25 dilutions of the serum. All rats, with the exception of those receiving normal rabbit serum, were completely protected against the subsequent injection of 3.3 X 108 CFU of M.
arthritidis. Indirect hemagglutinating and metabolic inhibiting antibody. At no time could indirect hemagglutinating or metabolic inhibiting antibody be detected in the sera of rats inoculated with M. arthritidis. Serum samples were taken at various stages of the disease and from animals injected with various doses of organisms. All sera were negative in these tests. On the other hand, rabbits immunized with M. arthritidis produced antibody titers of 1:10,240 in the MI test and 1:5,120 in the IHA test.
The ability of the rat to produce metabolic inhibiting antibody was further explored. M. arthritidis and six nonmurine species of mycoplasma were injected into rats using either of the following immunization procedures. (i) The hind foot pads were injected with 0.15-ml amounts of an antigen/adjuvant (Freund's complete) mixture; the rats were challenged 4 weeks later in the shoulder muscles and serum was collected after 10 days. (ii) Antigen suspension (0.15-ml amounts) was injected iv; after 2 weeks, the animals were challenged by the sc injection of an antigen/adjuvant mixture and serum was collected after 10 days.
Antisera prepared in rats against M. bovigenitalium, M. felis, and M. hyorhinis were tested for MI antibodies as indicated by inhibition of glucose fermentation. Rat antisera against M. arthritidis, M. hominis, M. gailinarum, and M. maculosum were tested for MI antibodies as indicated by inhibition of the arginine dihydrolase pathway. With the exception of M. arthritidis, all of the above species of mycoplasma induced metabolic inhibiting antibodies in the rat (Table 8) .
DISCUSSION Rats injected iv with M. arthritidis strain 158 PIO produced high levels of complementfixing antibody depending upon the number of organisms injected and upon the severity of the ensuing arthritis. An early, rapid rise in the level of CF antibody was observed. Although this is suggestive of a secondary response, no other evidence of previous exposure to M. arthritidis was encountered. Rats injected with similar numbers of Formalin-killed organisms developed a much less pronounced antibody response. Furthermore, we have demonstrated that nonmurine species of mycoplasma can also induce detectable complement-fixing antibodies in the rat 4 days after iv injection (unpublished data). This would suggest that the early rise in CF titers is a characteristic of the rat rather than an indication of a secondary response to a specific agent. Large doses of avirulent organisms or smaller doses of virulent M. arthritidis also give rise to poorer antibody responses.
Rats previously infected with M. arthritidis showed a high degree of resistance to reinfection. The degree of resistance was found to be correlated to the level of CF No growth-inhibiting antibody was found in rats injected with M. arthritidis. All tests for this antibody were negative, even when animals were subjected to repeated injections of the organisms in the presence of adjuvant. All of the nonmurine species of mycoplasma which were tested were capable of inducing growth-inhibiting antibody in the rat. These important observations suggest a possible mechanism for pathogenicity of M. arthritidis in rats. The failure of this species to induce growth-inhibiting antibody could be explained in several ways. First, the organisms could possess surface heterogenetic antigens in common with rat tissue. These could render the surface sites of the organisms less antigenic for the rat. Second, M. arthritidis may adsorb host antigens in vivo, thereby becoming less immunogenic in the host and thus able to survive longer. An alternative explanation of these findings would be in the development of immunological tolerance to certain M. arthritidis antigens as a result of prior exposure of the rats to these organisms.
Influenza virus provides an example of the adsorption of host antigens by a parasite (10, 11 ).
An example of heterogenetic antigens is shown with group A and group C streptococci. The capsules of these organisms consist of a polymer of hyaluronic acid, a substance which is present in the tissues of the host (24) . Since the streptococcal capsules are nonantigenic, phagocytosis of the organisms may be delayed, thus enabling the parasite to establish itself in the host. Zabriskie (24) has termed this phenomenon "biological mimicry." Antigenic similarities between virulent Salmonella typhimurium and mouse tissues have been described (18) Furthermore, some strains were noticeably more resistant to inhibition by specific antiserum than others. Finally, some strains failed to induce the production of specific MI homologous antibodies in chickens.
If heterogenetic antigens are factors in the development of rat arthritis, much still remains to be explained. So far, we have been unable to identify the serum factor responsible for protection. Major serological differences between virulent and avirulent M. arthritidis have not been detected, and neither seems capable of inducing MI antibodies in rats. The production in vivo of an extracellular toxin or spreading factor might account for virulence. Antibodies produced against this substance might not be detectable by the CF technique, which employs washed antigen. Furthermore, if antitoxins were responsible for immunity, these might not be absorbed from convalescent serum by washed antigen prepared in vitro. However, as avirulent strains are also capable of inducing immunity, at least small amounts of this toxin would have to be produced by these organisms.
Thus, several mechanisms may be involved in rat arthritis. The organisms may resist the primary defences of the host by possessing a heterogenetic antigen which renders them less immunogenic. An extracellular factor produced by the multiplying organisms may enable them to invade or damage host tissue, resulting in severe inflammation. Eventually, the infection could be brought under control by the formation of antibodies against the extracellular toxin.or by other immune mechanisms.
Our results clearly indicate that failure of a host to produce metabolic inhibiting antibodies against a specific parasite does not preclude a pathogenic role for that parasite. Sole reliance on the presence of metabolic inhibiting antibodies as indicators of active or past infection should, therefore, be avoided. In fact, the consistent failure to detect these antibodies should provoke further investigation.
These studies have presented several paradoxes. However, they point to future avenues of research for elucidating the mechanisms of pathogenicity and virulence of mycoplasmal diseases.
